Balyasny Asset Management LLC Fate Therapeutics Inc Transaction History

Balyasny Asset Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.65 - $3.94 $175,421 - $418,885	-106,316 Reduced 72.74%	39,836 $148,000
Q3 2023 Nov 14, 2023	SELL	$2.02 - $5.04 $172,998 - $431,640	-85,643 Reduced 36.95%	146,152 $309,000
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $299,589 - $414,768	62,939 Added 37.27%	231,795 $1.1 Million
Q1 2023 May 15, 2023	BUY	$4.24 - $11.12 $715,949 - $1.88 Million	168,856 New	168,856 $962,000
Q2 2018 Aug 14, 2018	SELL	$9.16 - $13.48 $126,664 - $186,401	-13,828 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$6.3 - $13.77 $176,910 - $386,675	-28,081 Reduced 67.0%	13,828 $135,000
Q4 2017 Feb 14, 2018	BUY	$3.94 - $6.64 $119,425 - $201,265	30,311 Added 261.35%	41,909 $256,000
Q3 2017 Nov 14, 2017	BUY	$2.6 - $4.31 $30,154 - $49,987	11,598	11,598 $46,000

179

113M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $127M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.